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Thanks to their biological properties, amniotic membrane (AM), and its derivatives are
considered as an attractive reservoir of stem cells and biological scaffolds for bone
regenerative medicine. The objective of this systematic review was to assess the benefit
of using AM and amniotic membrane-derived products for bone regeneration. An
electronic search of the MEDLINE—Pubmed database and the Scopus database was
carried out and the selection of articles was performed following PRISMA guidelines.
This systematic review included 42 articles taking into consideration the studies in which
AM, amniotic-derived epithelial cells (AECs), and amniotic mesenchymal stromal cells
(AMSCs) show promising results for bone regeneration in animal models. Moreover, this
review also presents some commercialized products derived from AM and discusses
their application modalities. Finally, AM therapeutic benefit is highlighted in the reported
clinical studies. This study is the first one to systematically review the therapeutic benefits
of AM and amniotic membrane-derived products for bone defect healing. The AM is a
promising alternative to the commercially available membranes used for guided bone
regeneration. Additionally, AECs and AMSCs associated with an appropriate scaffold
may also be ideal candidates for tissue engineering strategies applied to bone healing.
Here, we summarized these findings and highlighted the relevance of these different
products for bone regeneration.
Keywords: amniotic membrane, amniotic epithelial cells, amniotic mesenchymal stromal cells, bone, bone tissue
engineering, regenerative medicine, natural scaffold
INTRODUCTION
Reconstruction of large bone defects is a public health issue and a clinical challenge in
orthopedic, plastic, oral, and maxillofacial surgery (Tseng et al., 2008; Nauth et al., 2011). Over
the years, different strategies leading to the replacement of missing bone have been employed.
Autologous bone grafts remain the most commonly used procedure for bone defect treatment.
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However, their limited availability and the additional donor site
morbidity restrict their clinical applications (Delloye et al., 2007).
Tissue engineering and regenerativemedicine thus emerged as an
option to overcome the limitation of conventional tissue grafting.
In the field of bone regenerative therapies, various strategies
using bioactivemembranes, growth factors and/or stem cells have
been intensively proposed (Stahl and Yang, 2020).
In this context, the amniotic membrane (AM) has become
a highly attractive and easily accessible source of bioactive
biological tissue containing growth factors and stem cells
(Tamagawa et al., 2004; Ilancheran et al., 2009). AM is the
innermost layer of the placenta and represents the border of
the amniotic cavity, containing the amniotic fluid and the
fetus. The AM contains three layers: an epithelial layer (mainly
single) in touch with the amniotic fluid, a basement membrane
and an avascular stroma layer. Two cell types compose the
AM: amniotic-derived epithelial cells (AECs) and mesenchymal
stromal cells (AMSCs). They produce extra-cellular matrix,
different cytokines, and growth factors (Mamede et al., 2012).
They are also known to display immunomodulatory properties
and possess a pluripotent potential (Tamagawa et al., 2004;
Ilancheran et al., 2007; Parolini et al., 2008, 2009; Centurione
et al., 2018). No teratoma formation was reported in the
literature following AM-derived stromal cells administration in
vitro and in vivo (Parveen, 2018; Li et al., 2019; Liu et al.,
2021). Due to its large availability, its anti-inflammatory (Hao
et al., 2000) and anti-fibrotic (Ricci et al., 2013) properties,
its low immunogenicity (Kang et al., 2012a) as well as the
presence of mesenchymal stromal cells (Parolini et al., 2009)
and growth factors (Koizumi et al., 2000; Grzywocz et al., 2014),
AM has been used in therapy as a useful biological dressing
in medicine, especially in ophthalmology or dermatology, since
1910. Since then, some studies have shown that AM and
amniotic membrane-derived products are suitable for tissue
engineering applications (Toda et al., 2007; Farhadihosseinabadi
et al., 2018; Ramuta and Kreft, 2018) especially in the field of bone
regeneration. Indeed, AM and its derivatives have been assessed
in pre-clinical and clinical studies to this end.
First, it has been demonstrated that AM has the ability
to be osteodifferentiated in toto, thereby suggesting promising
results using this membrane in its entirety for bone regeneration
(Lindenmair et al., 2010). Some studies thus suggested its
potential as a biological alternative to membrane commonly
used for guided bone regeneration (i.e., xenogeneic collagen
membrane or synthetic membrane) (Gindraux et al., 2017; Aprile
et al., 2020). To this end, AM has been assessed in therapy using
different strategies: alone or associated with a bone substitute, as
a covering or filling material of a bone defect, fresh or preserved
(Fénelon et al., 2018a). To further improve its potential for bone
regenerative medicine applications, some pre-clinical studies also
reported the use of AM seeded with various types of stem cells
(Tsugawa et al., 2011; Akazawa et al., 2016; Takizawa et al.,
2019). Depending on these various usage strategies of AM, its
ability to favor bone healing is still discussed, thus requiring an
overview of its potential to favor bone healing within a given
mode of application.
Another alternative to bone grafting is represented by tissue
engineering cell-based strategies, which are aimed at achieving
new bone formation via biomaterials used in combination with
multipotent cells associated or not with bioactive molecules
(Stahl and Yang, 2020). Stem cells are thus one of the most
crucial components to fabricate these complex living constructs,
mainly by seeding these cells on an appropriate scaffold matrix,
on which they will grow and differentiate (Cancedda et al., 2003).
AECs and AMSCs can be successfully isolated fromAM and their
osteogenic differentiation potential have been well-established in
vitro (Ilancheran et al., 2007; Parolini et al., 2008, 2009; Díaz-
Prado et al., 2010; Leyva-Leyva et al., 2013; Centurione et al.,
2018). The ability of AECs or AMSCs associated to a scaffold,
namely a bone substitute, to improve bone regeneration has thus
been assessed in vivo (Tsuno et al., 2012; Barboni et al., 2013;
Jiawen et al., 2014; Rameshbabu et al., 2016). However, there is
no study summarizing techniques used to regenerate bone based
on amniotic cells regenerative therapies.
Actually, there is no consensus regarding the optimal usage
strategies of AM and its derivatives to promote bone healing.
Thus, the objective of this review was to assess the potential of
AM and its derivatives for bone regeneration and summarize how
they should be used.
MATERIALS AND METHODS
This systematic review was performed according to the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) (Swartz, 2011) and registered on PROSPEROdatabase
(N◦ CRD42019146785).
Focused Question
The following focused question was defined: “What are the best
strategies of using AM or AM-derived products in the field of
bone regeneration?”
Selection Criteria
All in vivo pre-clinical and clinical studies involving the AM
or AM cells for bone regeneration were included. Only studies
published in English with their abstracts available on database
were considered. In vitro studies, case reports and systematic
reviews were excluded. Moreover, studies in which the AM was
not separated from the chorion were also excluded.
Search Strategy
An electronic search was conducted on MEDLINE-PubMed and
SCOPUS databases, for articles published in English, up toMarch
2021. The following search combination was used: (“amnion” OR
“amniotic membrane” OR “amniotic cells”) AND (bone) AND
(“in vivo” OR “pre-clinical” OR “clinical”). The reference lists of
all publications selected were manually screened and additional
articles complemented the electronic search.
Screening Methods and Data Extraction
Two independent reviewers (ME and MF) performed the
article selection and data extraction. Titles and abstracts were
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first screened according to the question: “What are the best
strategies of using AM or AM-derived products in the field
of bone regeneration?” If the titles and abstracts answered this
screening question, full-text articles were then assessed. In case
of disagreement between the reviewers, articles were discussed
to decide the final outcome with the help of a third reviewer
(FG). Relevant information of each article was collected in the
data extraction tables, such as: general characteristics (authors
and year of publication), the species, the model used, the type
of amniotic products (membrane, stromal cells, and commercial
products) and their characteristics. We also recorded treatment
procedures, evaluation criteria, and the outcomes of included
studies. For missing data, the authors were contacted by email
to complete the information of the selected articles.
Analysis of the Data
Data analysis was performed in a descriptive way, since the
information obtained did not enable meta-analyses.
RESULTS
Search Outcomes
The electronic search generated 390 articles from MEDLINE-
PubMed database and 473 articles from Scopus database. After
reading the titles and abstracts, 36 articles were selected for
further investigation. The entire publications were read and
three articles were excluded. Nine articles were then added
after manual literature searches (Figure 1). Finally, 42 studies
met the eligibility criteria and were included to be analyzed in
this systematic review. Twenty-one pre-clinical studies reported
the use of AM for bone regeneration, while 10 other studies
were focused on AM-derived stromal cells. We also identified
seven clinical studies which investigated human AM therapeutic
benefits for bone regeneration. Finally, four studies investigated
the potential of commercialized products derived from AM for
bone regeneration.
Use of AM to Promote Bone Regeneration
in Animal Models
Among the 21 pre-clinical studies investigating the effectiveness
of AM for bone regeneration, two studies assessed its
osteoinductive potential using an ectopic bone formation model
(i.e., subcutaneous implantation), while all the remaining studies
were conducted on orthotopic models. We also identified several
AM usage strategies (Table 1). Most of the included studies used
human AM, whereas two animal studies were performed with
AM derived from rabbit or dog placenta. AM was either applied
over the bone defect or implanted as a filling material inside
the bone defect. Besides, AM was used either fresh (n = 5) or
preserved with different methods such as cryopreservation (n
= 8), lyophilization (n = 3), de-epithelialization (n = 2), and
decellularization (n= 7). Finally, AMwasmainly used alone or in
association with a bone substitute (n = 13) (Table 2). Otherwise,
AM was seeded with stromal cells before being implanted in
animal models (n= 8) (Table 3).
Ectopic Sites
Two studies showed the absence of osteoinductive potential of
AM for bone regeneration in a subcutaneous ectopic model in
mice. Subcutaneous implantation is the simplest experimental
model to assess ectopic bone formation, reducing the number of
variables involved in bone formation (i.e., stimulating cytokines,
bone forming cells, endogenous stem cells, and potentially
bone-stimulating mechano-transduction) (Scott et al., 2012). In
the first study, AM was assessed either fresh or after being
osteodifferentiated in vitro, combined or not with a bone
substitute (Table 2). Eight weeks after surgery, neither fresh nor
osteodifferentiated AM induced ectopic bone formation, whether
or not it was associated with the bone substitute (Laurent et al.,
2017). The second study investigated the efficacy of dental pulp-
derived cells (DPSCs) seeded on AM to induce bone formation
(Takizawa et al., 2019) (Table 3). The study compared DPSCs
sheets cultured in an osteoinductive or control culture medium.
Both sheets were grafted subcutaneously. Four weeks after
implantation 2D-Radiography, immunological and histological
analysis were performed. Qualitative staining suggested better
results with osteodifferentiated DPSCs sheets that showed higher
osteocalcin expression, and had higher alkaline phosphatase, von
Kossa, and alizarin red staining compared to the sheets cultured
in the control medium This study did not show quantitative
analysis and did not perform an osteoinductive positive control.
Orthotopic Sites
Eight studies assessed the efficacy of AM used alone to regenerate
surgical bone loss (Tables 1, 2). Samandari et al. studied the bone
remodeling of a jaw mucoperiosteal defect in dogs (Samandari
et al., 2011). Covering the defect with AM significantly enhanced
bone formation. Tang et al. were the first to assess the use of AM
as a barrier membrane for guided bone regeneration (Tang et al.,
2018). They showed that the implantation of AM over the defect
increased significantly bone formation compared to the femoral
defect left empty in rats. This result was corroborated by the
enhancement of gene expression connected with cell recruitment
and bone remodeling expression. Recently, Sari et al. investigated
the efficacy of wrapped AM to promote tibial bone shaft fracture
healing in rats (Sar et al., 2019). They observed that wrapping AM
circumferentially around the fracture line significantly promoted
fracture healing compared to the bone reduction without
membrane. The ability of AM to act successfully as a barrier
membrane for guided bone regeneration was also supported by
another study, which compared AM to a currently used collagen
membrane. In their study, Koushaei et al. also observed that
bone formation was significantly enhanced when the tibial defect
was covered by AM compared to the empty defect in dogs
(Koushaei et al., 2018). Additionally, no significant difference
in the amount of regenerated bone was evidenced between the
commercial collagen membrane and the empty defect, thereby
suggesting that AM is more effective than this commonly used
collagenmembrane to guide bone regeneration. The bone healing
potential of AM used as a membrane to cover bone defect was
also reported with larger bone defect models. Indeed, two studies
showed the efficacy of covering a rabbit segmental bone defect
with AM to promote bone regeneration (Ghanmi et al., 2018;
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FIGURE 1 | Flow diagram of the screened publications.
Moosavi et al., 2018). Finally, only two studies investigated the
influence of AM preservation methods on its bone regeneration
potential. One study investigated the impact of cryopreservation
on bone regeneration potential of AM compared to fresh AM.
The AM cell layer oriented toward the bone with the best
regeneration efficiency was also investigated. Results suggested
that the use of cryopreserved AM with the mesenchymal side in
contact with the calvarial defect was the best condition to favor
bone regeneration in mice (Fénelon et al., 2018b). The other
study compared four commonly used preservation methods
of AM (i.e., fresh, cryopreserved, lyophilized or decellularized,
and lyophilized) for GBR procedures in mice tibial defect
(Fenelon et al., 2020). Covering the defect with lyophilized
or decellularized and lyophilized AM significantly enhanced
early bone formation. One month after the surgery, only the
decellularized and lyophilized AM significantly promoted higher
bone regeneration.
Conversely, three studies suggested that using AM as a filling
material, instead of using it as a covering membrane, did not
promote bone regeneration but rather delayed it (Ghanmi et al.,
2018; Khalil and Melek, 2018; Moosavi et al., 2018). Khalil
et al. observed that bone formation was significantly lower when
AM was used to fill the femoral defect compared to the empty
defect in rabbits (Khalil and Melek, 2018). The two other studies
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TABLE 1 | AM usage strategies to treat bone defects in preclinical and clinical studies.
References AM origin AM preservation methods Number of layer AM disposition AM uses
Pre-clinical studies
Gomes et al. (2001) Human Lyophilized 2 On the base and
over the defect
Alone or combined with a
bone substitute
Samandari et al. (2011) Human Cryopreserved 1 Over the defect Alone
Li et al. (2015) Human Decellularized + Lyophilized 8 Over the defect Covering a bone substitute
Fénelon et al. (2018b) Human Fresh or Cryopreserved 1 Over the defect Alone
Cryopreserved 1 Over the defect Covering a bone substitute
Tang et al. (2018) Human De-epithelialized + Lyophilized 1 Over the defect Alone
Ghanmi et al. (2018) Human Fresh 1 Over the defect Alone
3 Into the defect
Khalil and Melek (2018) Human Lyophilized 1 Into the defect Alone
Koushaei et al. (2018) Human Cryopreserved 1 Over the defect Alone
Fenelon et al. (2020) Human Fresh/or Cryopreserved/or
Lyophilized/or Decellularized +
Lyophilized
1 Over the defect Alone
Moosavi et al. (2018) Human Fresh 1 Over the defect or
Into the defect
Alone or covering a bone
substitute
Li W. et al. (2019) Human Decellularized 2 Over the defect Alone or combined with a
polymer
Sar et al. (2019) Human Cryopreserved 1 Over the defect Alone
Tsugawa et al. (2011) Human De-epithelialized 1 Over the defect Alone or seeded with cells
Semyari et al. (2016) Rabbit Decellularized 1 Over the defect Alone or seeded with cells
Amer et al. (2015) Dog Cryopreserved 1 Into the defect Alone or seeded with cells
Wu et al. (2016) Human De-epithelialized 1 Into the defect Alone or seeded with cells
Akazawa et al. (2016) Human Decellularized 1 Over the defect Seeded with cells
Takizawa et al. (2019) Human De-epithelialized 1 Into the defect Seeded with cells
Sabouri et al. (2020) Human Decellularized 1 Over the defect Alone or seeded with cells
Dziedzic et al. (2021) Human Decellularized 4 Into the defect Alone or seeded with cells
Clinical studies
Kothiwale et al. (2009) Human Lyophilized 1 Over the defect Covering a bone substitute
Kiany and Moloudi (2015) Human Lyophilized 2 Over the defect Covering a bone substitute
Kumar et al. (2015) Human Lyophilized 1 Over the defect Covering a bone substitute
Sali and Pauline George
(2016)
Human Lyophilized 1 Over the defect Covering a bone substitute
Pajnigara et al. (2017) Human Lyophilized 1 Over the defect Covering a bone substitute
Kaur and Bathla (2018) Human Lyophilized 1 Over the defect Covering a PRF membrane
Akhlaghi et al. (2019) Human Decellularized + Lyophilized 1 Over the defect Covering a bone substitute
PRF, platelet-rich fibrin.
performed a rabbit segmental bone defect and compared, among
other things, the efficacy of AM as a membrane covering the
defect or filling the bone defect. They both observed a significant
higher bone formation when AM was used to cover the defect,
whereas no difference was evidenced between the empty defect
and the defect filled with AM (Ghanmi et al., 2018; Moosavi et al.,
2018).
Only one study used the AM hybridized with a synthetic
polymer (poly 1,8-octamethylene-citrate) to create a cell-free,
resorbable, tissue engineered graft for complete cleft palate. Li
et al. studied palate cleft healing using AM or AM combined
with the polymer in rats (Li W. et al., 2019). A complete
hard palate reconstruction with a complete bone union was
achieved by AM combined with the polymer compared to AM
used alone. Unfortunately, this study did not assess healing
using the polymer without AM, making thus difficult to draw
any conclusion.
Few studies investigated the additional osteoconductive
properties of AM associated with a bone substitute. Gomes et al.
performed a qualitative histological evaluation that showed a
greater amount of bone tissue and a faster bone healing process
when AM covered the bone substitute compared to AM alone in
a rabbit calvarial defect model (Gomes et al., 2001). Two studies
also investigated the potential of AM as a membrane covering
a bone substitute and compared it to a currently used collagen
membrane (Li et al., 2015; Fénelon et al., 2018b). Li et al. assessed










































TABLE 2 | Pre-clinical studies using AM alone and/or combined with a bone substitute for bone regeneration.

















2) MBCP + AM
3) MBCP +
Osteodifferentiated AM
Histology No ectopic bone formation was observed in any of the
tested conditions for both experimentations after 1, 2, 4,
and 8 weeks.
Samandari et al. (2011) Dog (No. = 20) Mucoperiosteal defect in jaw
7 × 5 cm2
1) Orabase® dressing
2) AM covered by
Orabase® dressing
Histology AM significantly increased bone remodeling after 2, 8,
and 12 weeks.







AM significantly increased bone formation after 15 and
30 days.
AM induced a significant higher expression of gene
connected with cell recruitment and bone remodeling.
Koushaei et al. (2018) Dog (No. = 6, No. = 5,






Histology AM significantly increased bone formation compared to
the defect left empty after 6 and 12 weeks. No significant
differences between collagen membrane and the defect
left empty.
Ghanmi et al. (2018) Rabbit (No. = 5) Tibial segmental defect
20mm
1) Empty defect (periosteum +)
2) Empty defect (periosteum –)
3 ) AM over the defect
(periosteum –)





AM implanted over the defect group increased
significantly bone regeneration compared to groups 1
and 4 after 4 and 8 weeks. Bone healing was even more
promoted by the natural periosteum.
Khalil and Melek (2018) Rabbit (No. = 6) Femoral defect
4 × 5mm
1) Empty defect
2) AM into the defect
Histology Woven bone was observed as early as the second week
in the empty defect, whereas AM defect was filled by
fibrous tissue and AM.
Bone formation was significantly reduced in AM group
after 2, 4, and 6 weeks compared to the empty group.
Sar et al. (2019) Rat (No. = 7) Tibial defect
Shaft fracture
1) Fracture fixation




AM increased significantly bone formation and callus
diameters after 3rd and 6th weeks.




2) Fresh AM MES
3) Cryo AM MES
4) Fresh AM EPI










































































































TABLE 2 | Continued










2) HA + Collagen membrane
3) HA + Cryo AM MES
4) HA + BMP2 membrane
5) HA + BMP2 + Collagen
6) HA + BMP2 + Cryo AM MES
2D X-rays
Histology
Cryopreserved AM with mesenchymal side in contact
with the defect increased significantly bone formation
after 8 weeks. No significant differences between HA
group, HA + AM group and HA + collagen membrane
group after 6 weeks.
Gomes et al. (2001) Rabbit (No. = 3) Calvarial defect
10 × 5mm
1) AM
2) ADDM + AM
Histology Newly formed bone was observed in both groups after
30 days. Mature bone tissue was observed in both
groups after 120 days.
Bone healing was faster in ADDM + AM group.
Li et al. (2015) Rat (No. = 6) Tibial defect










The gray level of the collagen and the AM groups were
significantly higher than Bio-oss® group after 6 weeks.
No significant differences were found between the AM
group and the no defect group.
A better bone–implant connection was also evidenced in
the AM group.
Moosavi et al. (2018) Rabbit (No. = 10) Radius segmental defect
15mm
1) Empty defect
2) AM into the defect
3) AM over the defect
4) DBM + AM over defect
2D X-rays
Histology
Bone formation was observed when AM was implanted
over the defect whereas group 1 and 2 showed no bone
compared to the three other groups after 8 weeks.
A small amount of bone was evidenced filling the defect
with DBM + AM.










AM improved significantly bone healing but AM-POC
allowed a complete closure of palate cleft and a
significantly better palate growth than AM alone after 2
months.
AM induced significantly more blood vessels than
AM-POC.










Covering the defect with lyophilized or decellularized and
lyophilized AM significantly enhanced early bone
formation. One month after the surgery, the
decellularized and lyophilized AM was the only
membrane which significantly increased bone formation
compared to the defect left empty.
Covering the defect with lyophilized or decellularized and
lyophilized AM resulted in a significant increase in blood
vessels density.
ADDM, autogenous demineralized dentin matrix; AM, amniotic membrane; Cryo, cryopreserved; DBM, demineralized bone matrix; EPI, epithelial side; HA, Hydro Hydroxyapatite; MBCP, synthetic biphasic calcium phosphate bone









































































































TABLE 3 | Pre-clinical studies using AM seeded with stromal cells to promote bone regeneration.


















KUSA-A1 cell line (n =
7.8 × 104 cells)
1) Empty defect
2) AM
3) AM + injected
KUSA-A1
4) AM-KUSA-A1
Up to 20 h 3D X-Ray
Histology
AM seeded with KUSA-A1 significantly increased
bone formation compared to other conditions after
5 weeks.
Semyari et al. (2016) Rabbit (No. = 1) Calvarial defect
8mm diameter
Rabbit ADMSC (n = 1







6h Histology All seeded scaffolds boosted significantly bone
regeneration compared to scaffolds alone after 4
weeks whereas no significant difference was
observed after 8 weeks.
Amer et al. (2015) Dog (No. = 3) Segmental femoral
defect
Length: 2 cm
Dog BMSC (n = NS) 1) Empty defect
2) AM
3) AM-BMSC
1 week 2D X-ray
Histology
AM and AM-BMSCs increased bone healing
compared to the empty defect after 6, 12, and 24
weeks.
Wu et al. (2016) Rat (No. = 5) Alveolar defect
Size: 2.6 × 2.0 ×
2.0mm






5 days 3D X-Ray AM and seeded AM significantly induced more bone
formation than the two other groups after 29 days
without significant difference between AM and
seeded AM.
Akazawa et al. (2016) Mice (No. = 10) Calvarial defect
3.75mm diameter
Human PDLSC and






AM-PDLSC-OB significantly enhanced bone
regeneration compared to AM seeded with one cell
type after 2, 4, and 8 weeks.
Takizawa et al. (2019) Mice (No.: NS) Subcutaneous
implantation








AM-hDPSCs in osteogenic medium expressed
more bone feature than hAM-hDPSCs in control
medium on ectopic site after 4 weeks.











4 weeks 3D X-Ray Osteodifferentiated hDPSCs seeded on AM
increased significantly alveolar bone formation after
4 weeks.
Sabouri et al. (2020) Rat (No. = 4) Calvarial defect
6mm diameter









Both seeded scaffolds significantly enhanced bone
regeneration compared to scaffolds alone after 4
and 8 weeks. The best results were achieved by the
MAM-seeded scaffold.
Dziedzic et al. (2021) Rat (No. = 5) Calvarial defect
8mm diameter
Rat ADSC (n = 5 ×






AM-ADSC significantly enhanced bone regeneration
compared to the empty defect after 12 weeks. No
significant difference between AM and AM-ADSC.
ADMSC, adipose-derived mesenchymal stromal cells; ADSC, adipose-derived stromal cells; AM, amniotic membrane; BMSC, bone marrow mesenchymal stromal cells; DAM, decellularized amniotic membrane; DPSCs, dental pulp-
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the potential of AM associated with a bone substitute in a rat
tibial defect surrounding a cylindrical titanium screw mimicking
guiding bone regeneration around a dental implant (Li et al.,
2015). The AM seemed to better avoid invasion of fibrous tissue,
thus promoting more bone healing than the collagen group. In
a previous study, we also compared AM and a commercially
available collagenmembrane to cover a bone substitute associated
or not with the BMP-2 growth factor in a mouse calvarial bone
defect model (Fénelon et al., 2018b). However, this study failed
to evidence any significant difference between groups without
membrane and groups covered by a collagen membrane or AM.
Finally, eight studies proposed the use of AM as a scaffold,
which could be seeded by stromal cells before its implantation
(Tables 1, 3). We identified seven types of stromal cells, which
have been seeded on AM to promote bone regeneration. Among
them six were primary cells whereas one study used cell line
(Tsugawa et al., 2011). They were cultured on AM for 6 h and
up to 4 weeks before its implantation in vivo. Tsugawa et al.
investigated the potential of using AM as a scaffold seeded with
a bone marrow derived stromal cell line prior its implantation in
a mouse calvarial bone defect model (Tsugawa et al., 2011). They
observed earlier and greater bone regeneration of calvarial defect
with the seeded AM. Amer et al. performed qualitative analysis
of bone regeneration in a dog femoral segmental bone defect and
stated that AM and dog bone marrow mesenchymal stromal cells
(BMSCs)-seeded AM enhanced bone healing compared to the
empty condition (Amer et al., 2015). They also reported that bone
regeneration occurred sooner when AM was seeded with BMSCs
before its implantation. However, no quantitative analysis was
present in this study to support the results. Three studies
investigated the ability of AM to act as a scaffold seeded with
adipose derived stromal cells (ADSCs) for bone regeneration.Wu
et al. reported that bone regeneration was significantly enhanced
when the rat alveolar defect was filled with AM or human
ADSCs-seeded AM compared to the empty defect or defect filled
with cells (Wu et al., 2016). No statistical difference between
AM and seeded AM was evidenced in this study. Dziedzic et al.
showed a significant higher bone formation using seeded AM
compared the defect left empty (Dziedzic et al., 2021). However,
they also failed to evidence significant difference between AM
and seeded AM in contrast with the study of Semyari et al. which
observed an earlier bone regeneration when rabbit ADSCs-
seeded AM was implanted in a rabbit calvarial bone defect
(Semyari et al., 2016). However, almost complete defect closure
was observed in all experimental groups after 8 weeks. Akazawa
et al. investigated the bone regeneration potential of AM seeded
with two different stromal cells types (human periodontal
ligament stem cells and calvarial osteoblasts) either together or
separately (Akazawa et al., 2016). Significant better results were
achieved when the two cell types were combined and seeded
on AM using a calvarial bone defect in mice. Takizawa et al.
compared the suitability of AM seeded with human DPSCs after
being cultured in vitro in two different conditions (osteogenic
or control medium) (Takizawa et al., 2019). X-ray showed a
significant bone-like tissue outgrowth when the cell-seeded AM
had been cultured in osteogenic medium prior to its implantation
in a rat alveolar defect. However, this study lacks histological data
to support this result. Finally, Sabouri et al. proposed a novel
approach by mineralizing AM before cell-seeding (Sabouri et al.,
2020). They stated that themineralized and seeded AMpromoted
higher bone regeneration than conventional seeded AM.
Use of AM to Promote Bone Regeneration
in Clinical Studies
The seven included clinical studies on the osteogenic potential of
the membrane were all performed in the field of oral andmaxillo-
facial surgery (Table 4). They used AM as an allograft membrane
and AM was mostly processed as a lyophilized membrane (n =
6), otherwise the membrane was decellularized then lyophilized
(n= 1) (Table 1) (Akhlaghi et al., 2019). AM was used to cover a
bone substitute in six studies.
Kaur et al. showed that bone formation was enhanced
when periodontal furcation defects were filled with a platelet-
rich fibrin (PRF) membrane then covered by AM (Kaur and
Bathla, 2018). However, it is more widely recognized to use
a bone substitute rather than a PRF membrane as a filling
material to treat periodontal defects. The first randomized
clinical trial investigating the potential of AM covering a
bone substitute to guide bone regeneration was performed
by Kothiwale et al. (2009). This study compared two groups,
which both used AM and assessed its efficacy to cover either
xenogeneic or allogenic bone grafts for periodontal furcation
defect treatment. They stated that this association significantly
improved bone formation. Unfortunately, there was no control
group without the membrane to specifically highlight its effect.
Three studies were then performed to compare bone formation
with or without AM in the field of periodontal surgery. Kumar
et al. filled periodontal pockets with hydroxyapatite bone graft,
which was covered or not by AM (Kumar et al., 2015). They
showed a significant improvement of clinical and radiological
parameters using AM to cover the bone substitute. This was
corroborated by Pajnigara et al. who displayed similar results
for the treatment of periodontal furcation defect (Pajnigara
et al., 2017). The association of a bone allograft with AM
resulted in a more significant quantity of regenerated tissue than
the bone substitute alone. However, contradictory results were
obtained by Sali et al., which observed similar improvement
of periodontal pockets regeneration using or not AM to cover
the bone substitute (Sali and Pauline George, 2016). This study
was conducted on a smaller sample size than the two above-
mentioned studies. Interestingly, one study compared AM to
a commercial resorbable collagen membrane commonly used
in oral surgery (Kiany and Moloudi, 2015). Both membranes
were applied over a bone xenograft to treat periodontal pockets.
No significant difference was observed between this resorbable
collagen membrane, gold standard for this application, and AM
after 6 months, thereby demonstrating that AM could be a
promising alternative.
Finally, one clinical study investigated the potential of AM
to favor large bone defect healing in jaws. Akhlaghi et al. used
a decellularized AM in combination with autologous buccal fat
pad-derived stem cells to cover large bone grafts prior to implant
placement (Akhlaghi et al., 2019). They reported a better healing










































TABLE 4 | Clinical studies using amniotic membrane to guide bone regeneration.
References No. = (Patients per
group)
Indication Treatments Evaluation methodology Results
Kothiwale et al. (2009) No. = 10 Periodontal furcation
defect (Grade II)
1) DFDBA + AM
2) Bio-oss®+ AM
Measurement of CAL and
PPD
2D Radiography
Significant improvement of parameters from baseline to 9
months in both groups without significant differences
between groups.
Kiany and Moloudi (2015) No. = 10 Periodontal pockets 1) Bio-oss®+ AM
2) Bio-oss®+ Collagen
membrane (Bio-gide®)
Measurement of CAL, PPD,
GR, and probing bone
Significant improvement of parameters from baseline to 6
months in both groups. No significant differences between
the two groups after 6 months.
Kumar et al. (2015) No. = 27 Periodontal pockets 1) G-graft®
2) G-graft® + AM
Measurement of CAL, PPD,
and inflammatory
2D Radiography
AM significantly increased bone fill and CAL after 6 months.
Sali and Pauline George
(2016)
No. = 10 Periodontal pockets 1) DFDBA
2) DFDBA + AM
Measurement of CAL, PPD,
and GR
3D Radiography
Significant improvement of parameters from baseline to 12
months in both groups. No significant differences between
the two groups at 12 months.
Pajnigara et al. (2017) No. = 20 Periodontal furcation
defect (Grade II)
1) DFDBA
2) DFDBA + AM
Measurement of CAL, PPD,
GR, and horizontal probing
depth
3D Radiography
AM increased significantly bone fill and CAL at 6 months. AM
reduced significantly PPD and GR at 6 months.
Kaur and Bathla (2018) No. = 15 Periodontal furcation
defect (Grade II)
1) PRF
2) PRF + AM
Measurement of CAL and
PPD
3D Radiography
AM significantly increased bone fill and CAL at 6 months. AM
significantly reduced PPD at 6 months.
Akhlaghi et al. (2019) No. = 9 Jaw-bone defect 1) NBBM+ bone autograft + AM
2) NBBM + bone autograft +
AM loaded with BFSCs
3D Radiography
Histology
The mean increase in bone width was significantly greater in
the AM + BFSCs group at 5 months.
AM, amniotic membrane; BFSCs, buccal fat pad-derived stromal cells; CAL, clinical attachment level; DFDBA, demineralized freeze dried bone allograft; GR, gingival recession; NBBM, natural bovine bone mineral; PPD, probing pocket
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of jaw-bone defect when the bone graft was covered with AM
loaded with stem cells compared to AM alone. However, there
was no membrane-free group from which to draw conclusions
about the role of AM in the healing process.
Use of Amniotic Cells to Promote Bone
Healing
Ten studies assessed in vivo the potential of AECs and AMSCs as
a source of cells for bone regenerative therapies (Table 5). A bone
substitute was used as a scaffold in five studies. The cell culture
duration after seeding the scaffold and before its implantation
was 3–42 days.
Ectopic Sites
A mouse ectopic model was used in two studies to assess the
osteoinductive potential of amniotic membrane cells seeded on
a biomaterial. These are the only studies that clearly specified
that AECs and AMSCs were first cultivated in an osteoinductive
medium before being seeded on the scaffold and then implanted.
Chen et al. (2014) created an in vitro perfusion culture system
to irrigate the AMSCs-seeded scaffold before its implantation
in vivo and compared it to the same AMSCs-seeded scaffold,
which was only cultured in osteogenic medium without being
followed by perfusion. Better results were achieved using the
perfusion culture system. Si et al. compared the osteogenic
potential of AECs seeded on a bone substitute to two other types
of stromal cells including gold standard human BMSCs (Si et al.,
2015). No subcutaneous bone formation was observed whatever
the condition tested. However, bone associated extracellular
matrix proteins seemed to show higher staining with the
seeded scaffolds.
Orthotopic Sites
Eight studies investigated the potential of AECs or AMSCs seeded
on a scaffold to regenerate bone defects (Table 5). Three studies
assessed in vivo the use of AECs seeded on a scaffold to the
scaffold implanted alone for bone regeneration. They all reported
that AECs display osteogenic potential.Mattioli et al. performed a
qualitative histological analysis in a sheep tibial defect model and
observed that ovine AECs-transplanted defects were filled with
newly deposited bone whereas only fibrous tissue was observed
in the fibrin glue control defects (Mattioli et al., 2012). In the two
other studies, AECs were seeded on an osteoconductive scaffold
(i.e., bone substitute). Barboni et al. reported the ability of ovine
AECs seeded scaffold to significantly promote bone regeneration
and maturation in sheep sinus augmentation surgery compared
to the scaffold without cells (Barboni et al., 2013). This was
corroborated by Jiawen et al. which showed a significant increase
in bone formation and a decrease in inflammatory reaction
using human AECs seeded scaffold compared to the non-seeded
scaffold after 1 and 2 months in rat alveolar defects (Jiawen et al.,
2014).
Five studies assessed in vivo the potential of AMSCs seeded
scaffold to promote bone regeneration. Tsuno et al. stated that
more bone deposition was observed with human AMSCs seeded
on an osteoconductive scaffold compared to the non-seeded
scaffold in a rat calvarial defect model (Tsuno et al., 2012).
Rameshbadu et al. investigated the osteogenic potential of human
AMSCs in an osteochondral bone defect in rabbits (Rameshbabu
et al., 2016). They observed higher osteochondral bone formation
with the AMSC seeded scaffold. Two other studies also reported
significantly higher bone regeneration using hAMSCs seeded
scaffold compared to the non-seeded scaffold (Li et al., 2020;
Datta et al., 2021). Only one study compared a “hAMSCs seeded
scaffold” to the same cells implanted alone without the scaffold.
Both groups containing hAMSCs (with or without the scaffold)
showed significantly higher bone formation in a rabbit calvarial
defect (Jiang et al., 2020).
Commercialized AM-Derived Products for
Bone Regeneration
Four studies used commercialized AM-derived products to
promote bone healing in pre-clinical and clinical settings
(Table 6). Two studies reported the use of the commercial
preparation NuCel R© associated with a bone autograft. NuCel R©
is an amniotic suspension allograft, derived from human AM
and amniotic fluid cells that is cryopreserved to maintain
bioactivity. Starecki et al. assessed the bone regeneration potential
of NuCel R© mixed with a bone graft in a rat segmental bone
defect (Starecki et al., 2014). Bone graft preparation mixed with
NuCel R© did not improve bone formation compared to the
bone graft group after 6 weeks. One clinical study proposed to
perform lumbar interbody fusion in patients using bone allograft
mixed with NuCel R© (Nunley et al., 2015). This retrospective
analysis showed that 97.4% of one-level patients and 100%
of two-level patients were clinically fused. These results were
similar to those found in the literature for conventional lumbar
interbody fusion procedure. Konofaos et al. investigated the
potential of another commercialized preparation, which is the
AmnioMTM R©, to promote bone healing of rat calvarial defects
(Konofaos et al., 2015). This product is an injectable gel
obtained after grinding cryopreserved amnion. In this study,
the AmnioMTM R© was mixed with a bone substitute before
grafting. Contradictory findings were obtained after 1 month
of implantation. Micro-CT data showed that the addition of
AmnioMTM R© to the bone substitute did not significantly
increase new bone formation compared to the grafted bone
substitute alone, though statistical difference was observed with
histomorphometric analysis. Finally, Burdette et al. reported the
use of a secretome (ST266, Noveome Biotherapeutics) derived
from cultured human amniotic cells for bone formation in a rat
calvarial defect (Burdette et al., 2017). The secretome is a liquid
suspension containing biomolecules released by amniotic cells.
Micro-CT analysis showed no significant difference in terms of
bone volume regenerated, whereas the secretome significantly
enhanced bone density.
DISCUSSION
This article aimed at reviewing the bone regenerative medicine
approaches of AM and its derivatives as well as their limitations.
We outlined that three categories of AM-derived products
were mainly used for bone regeneration: (i) AM (ii) AM cells, and










































TABLE 5 | Pre-clinical studies using amniotic membrane derivated stromal cells for bone regeneration.

















Mattioli et al. (2012) Sheep (No. = 2) Tibial defect
Diameter: 3mm






2) Tissuecol + oAECs
Histology Bone deposition was only observed in
oAECs-transplanted defects after 45 days.
Tsuno et al. (2012) Rat (No. = 3) Calvarial defect
Diameter: 5mm
hAMSCs (1 × 107
cells/mL)
β-TCP (t = NS) 1) β-TCP
2) β-TCP + hAMSCs
Histology hAMSCs seeded scaffold showed immature bone
deposition at 6 weeks and mature bone areas at 12
weeks.
Barboni et al. (2013) Sheep (No. = 3) Sinus augmentation oAECs (1 × 106
cells)
HA/β-TCP (t = 3
days)
1) HA/β-TCP
2) HA/β-TCP + oAECs
Micro-CT
Histology
oAECs seeded scaffold displayed significant earlier
bone formation and maturation at 45 days and
induced significantly more bone deposition at 90
days.






1) CultiSpher S+ hAMSCs (no
perfusion)
2) CultiSpher S+ hAMSCs (1
week perfusion)




Perfusion culture system increased mineralized
matrix after 6 and 12 weeks Perfusion significantly
enhanced vessel density.
Jiawen et al. (2014) Rat (No. = 4) Alveolar defect
Size: NS
hAECs (1.5 × 106) β-TCP (t = 3 days) 1) β-TCP
2) β-TCP + hAECs
Micro-CT
Histology
hAECs seeded scaffold significantly increased bone
formation at 4 and 8 weeks postoperatively. hAECs
seeded scaffold showed a significantly delayed
macrophage response.
Si et al. (2015) Mice (No. = 3) Subcutaneous hAECs (1.5 × 106) β-TCP (t = 3 days) 1) β-TCP
2) β-TCP + hBMSCs
3) β-TCP + hAFMSCs




No sign of mineralization in all groups 1 month after
implantation. OPN and OCN were expressed at a
higher level with the seeded scaffolds.
Rameshbabu et al.
(2016)
Rabbit (No. = 5) Osteochondral defect
Diameter: 4 mm
Deep: 5mm
hAMSCs (NS) PEMS (7 days) 1) Empty defect
2) PEMS
3) PEMS + hAMSCs
Histology hAMSCs seeded scaffold seemed to induce higher
bone formation and osteochondral regeneration 60
days post-implantation.
Jiang et al. (2020) Rabbit (No. = 3) Calvarial defect
Diameter: 10mm













Bone regeneration was significantly higher in groups
3 and 4 after 4 and 12weeks. Fluorescent labeling
was significantly higher in group 4 after 3, 6, and 9
weeks. Vessels-like structure are significantly higher
in presence of hAMSCs.
Li et al. (2020) Rat (No. = 3) Calvarial defect
Diameter: 3mm
hAMSCs (1 × 106
cells/mL)
Fibrin (NS) 1) Fibrin
2) Fibrin + hAMSCs
Micro-CT
Histology
hAMSCs seeded scaffold induced significantly
higher bone formation after 8 weeks.
Datta et al. (2021) Rabbit (No. = NS) Tibial defect
Diameter: 2.5 mm
Deep: 2mm






3) Hydrogel + hAMSCs
Micro-CT
Histology
Bone regeneration was significantly higher using
hydrogel + hAMSCs after 4 and 8 weeks. hAMSCs
seeded scaffold showed more vascular structure
after 4 weeks compared to the two other groups.
β-TCP, β-tricalcium phosphate; DBM, demineralized bone matrix; HA, hydroxyapatite; hAECs, human amniotic epithelial cells; hAMSCs, human amniotic mesenchymal stromal cells; NS, Not specified; oAECs, ovine amniotic epithelial

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(iii) commercialized AM-derived products. Most of the included
studies investigated the use of AM as a membrane for bone
regeneration. AM is a promising natural allogenic biomaterial
which is widely available without ethical concerns. Moreover,
compared to collagen or synthetic membranes commonly used
for guided bone regeneration procedures, AM displays several
biological properties making it very attractive for this field
(Gindraux et al., 2017; Fénelon et al., 2018a; Aprile et al.,
2020; Gulameabasse et al., 2020). AM promotes epithelialization,
namely by excreting epithelial growth factor (EGF) (Jin et al.,
2016) and has also the ability to modulate angiogenesis (Niknejad
et al., 2013). In addition, AM has antimicrobial activity by
expressing natural antimicrobial molecules such as β-defensins
and elafin (King et al., 2007) and shows anti-fibrotic properties,
due to secretion of tissue inhibitors of metalloproteinase (TIMPs)
and the down-regulation of transforming growth factor beta
(TGF-β) in fibroblasts, which is responsible for their activation,
thereby reducing the risk of adhesion and scarring (Lee et al.,
2000; Ricci et al., 2013). These biological properties, as well as
mechanical properties of AM, might be modulated or affected by
the preservation process (Yazdanpanah et al., 2015; Fenelon et al.,
2019).
Thanks to its low immunogenicity, all but two studies (Amer
et al., 2015; Semyari et al., 2016) used human AM either as a
xenograft or as an allograft. AM is known to be an immune-
privileged tissue and to contain some immunoregulatory factors,
including HLA-G (an immunosuppressive factor) and Fas
ligand (Kubo et al., 2001). This effect is also supported by
the low/absent level of expression of HLA class I molecules
and the absence of HLA class II molecules (Ilancheran et al.,
2009), avoiding allograft or xenograft rejection of human AM.
We identified several methods of preparation of AM in pre-
clinical studies. AM was used either fresh, cryopreserved, or
lyophilized (i.e., freeze-dried). Moreover, preserved AM has
been applied intact, de-epithelialized or decellularized (without
epithelial and mesenchymal stromal cells). Unfortunately, none
of the included studies has simultaneously compared these
preservation methods, making it difficult to conclude if there is
an optimal preservation method of AM for bone regeneration.
The wide heterogeneity of animal models (species, localization
and size of the defect) increases the difficulty of comparing these
conditioning methods. One study compared four commonly
used preservation methods of AM (i.e., fresh, cryopreserved,
lyophilized, and decellularized-lyophilized AM) using the same
animal diaphyseal bone defect model in mice (Fenelon et al.,
2020). No significant difference was observed between the empty
defect and the defect covered either by fresh or cryopreserved
AM, whereas lyophilized and decellularized-lyophilized AM
significantly enhanced early bone regeneration. Interestingly,
both methods are used when AM is applied to guide bone
regeneration in humans (Kothiwale et al., 2009; Kiany and
Moloudi, 2015; Kumar et al., 2015; Sali and Pauline George, 2016;
Pajnigara et al., 2017; Kaur and Bathla, 2018; Akhlaghi et al.,
2019). This result can be explained by the safe and long term
storage of samples at room temperature allowed by lyophilization
(Rodríguez-Ares et al., 2009), which could also be easily followed
by gamma irradiation to sterilize the membrane (Gindraux et al.,
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2013). Dehydration is another reported preservation procedure
of AM (Dadkhah Tehrani et al., 2020). Although this method is
used for gingival recession or mucosal defect treatments in oral
surgery (Fénelon et al., 2018a), none of the studies included in
the present review used dehydrated AM for bone regeneration.
Most of the studies which investigated the ability of AM to
act as a scaffold seeded with stem cells before its implantation
in bone defects used de-epithelialized or decellularized AM
(Tsugawa et al., 2011; Akazawa et al., 2016; Semyari et al.,
2016; Wu et al., 2016; Takizawa et al., 2019). This could be
related to the exposure of the basement membrane caused
by the de-epithelialization or decellularization process, thereby
promoting AM ability to favor cell adhesion and proliferation
(Koizumi et al., 2007; Riau et al., 2010; Salah et al., 2018;
Fenelon et al., 2019).We believe that the decellularization process
induce less variability and is more reproductible than a de-
epithelialization which is often required a scraping step that is
operator-dependent (Fenelon et al., 2019). Most of the included
studies pointed that AM is mainly applied as a single layer.
Few studies suggested to create a multilayered AM (Li et al.,
2015; Dziedzic et al., 2021). This might enhance its thickness
that initially ranges from 0.02 to 0.5mm (Bourne, 1962). In this
respect, a recent study demonstrates that AM epithelium is not
single-layered in the different regions (Centurione et al., 2018),
thus AM from the central region could be more appropriate
to transplant when a greater thickness is requested. However,
while AM is a thin membrane, several authors reported that
AM is easy to handle and to adapt to the surgical site (Tsuno
et al., 2014; Kiany and Moloudi, 2015; Fénelon et al., 2018a).
Our results also showed that AM was mainly used as a barrier
membrane covering bone defects. Otherwise, AM was applied
as a filling material inside the bone defect area. We observed
that better results were achieved when AM was used to cover
the defect rather than as a filler since grafting the AM into
the bone defect seems to hinder the bone regeneration process
(Ghanmi et al., 2018; Khalil and Melek, 2018; Moosavi et al.,
2018). This allows us to conclude that it is better to apply
AM over the defect acting as a barrier membrane, thereby
preventing the bone defect area from fibrous tissue invasion. This
occlusive function is one of the main characteristics required
for membranes used in guided bone regeneration procedure
(Aprile et al., 2020). We did not find information concerning
the space maintenance ability of AM which is another needed
criteria for membranes in guided bone regeneration procedures
(Naung et al., 2019). However, unlike some animal studies,
almost all clinical studies used a bone substitute that was then
covered by AM (Kothiwale et al., 2009; Kiany andMoloudi, 2015;
Kumar et al., 2015; Sali and Pauline George, 2016; Pajnigara
et al., 2017; Akhlaghi et al., 2019). Maintaining the space with
a bone substitute to support the membrane is often mandatory
with biological membrane which lacks mechanical properties to
avoid membrane collapse within the defect during the healing
(Bunyaratavej and Wang, 2001; Soldatos et al., 2017). Only few
studies compared AM with conventional membranes used for
guided bone regeneration procedures (Kiany and Moloudi, 2015;
Li et al., 2015; Fénelon et al., 2018b; Koushaei et al., 2018). It was
then compared to collagen membranes which are the resorbable
natural membranes most used for guided bone regeneration
(Bunyaratavej and Wang, 2001; Aprile et al., 2020). Preserved
AM (cryopreserved, decellularized or lyophilized) seemed to
be at least as efficient as these conventional and commercially
available membranes. AM seemed superior in avoiding fibrous
tissue invasion that could be linked to its anti-fibrotic properties.
However, it is noteworthy that very few studies have focused on
the resorption rate of AM even though it is a parameter often
criticized in conventionally used resorbable membranes. When
mentioned, the resorption duration of AM ranged from 1 to 2
months (Fénelon et al., 2018b; Tang et al., 2018). Thanks to its
biological properties and growth factors content, AM has become
a very attractive bioactive membrane for bone regeneration.
Similarities between AM and the induced membrane (Masquelet
technique) have even been shown (Gindraux et al., 2017).
The induce membrane is an autologous biological membrane
currently used to treat segmental long bone defects and
required a two-step surgical procedure. Both membranes share
similar proteins components, have comparable thickness, contain
growth factors such as VEGF or TGF-β1 and express anti-
inflammatory proteins (Pelissier et al., 2004; Grzywocz et al.,
2014; Gindraux et al., 2017; Litwiniuk et al., 2018). The use
of AM as an existing biological membrane could simplify this
approach into a one-step procedure, which would reduce risk
to the patient and surgical costs (Fénelon et al., 2021). Besides,
the absence of calcification detected in an ectopic model, namely
after subcutaneous implantation of AM (Laurent et al., 2017),
suggest the immune tolerance of AM (Wilshaw et al., 2008). It
is assumed that tissue rejection involves calcinosis and structural
degeneration of the graft that are caused by immune response
against donor cells (Muratov et al., 2010). In this systematic
review, most of the experiments assessing bone regeneration
using AM were performed in an orthotopic site, mimicking the
mechanical and chemical influences that bone receives in clinical
applications. In animal studies, the orthotopic evaluation of AM
was mainly performed using cranial, maxillary or mandibular
bone defects, otherwise long bone defects were used. This is
consistent with clinical studies which are all dedicated to oral and
maxillofacial surgery.
To further enhance the osteogenic potential of AM and
develop a qualifiable functional engineered product, some
authors suggested to seed stem cells on AM before its
implantation. These studies showed that AM displays the ability
to act as an appropriate natural scaffold, on which stem
cells can grow and differentiate toward the osteogenic lineage.
However, it is difficult to draw any conclusions from these
studies and to discern the effect of AM from the stromal
cells used on bone regeneration. First, contradictory results
were observed. Indeed, two studies reported an enhancement
of bone regeneration using either AM or seeded AM (Amer
et al., 2015; Wu et al., 2016), suggesting that using stromal
cells seeded on AM did not further enhance bone regeneration,
whereas an increase in bone regeneration was reported with
seeded AM compared to AM in three other studies (Tsugawa
et al., 2011; Semyari et al., 2016). Furthermore, only one
study was conducted using a defect filled with “stromal cells
only” as a control group (Wu et al., 2016), whereas all
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TABLE 7 | Strategies suggestion to perform a study on AM or AM derived products in the field of bone regeneration.
AM use strategy Preparation method Disposition Use Study design Expected results








with a bone substitute
1. Defect
2. Defect + AM
3. Defect + bone substitute
4. Defect + bone substitute
covered by AM
5. Defect + bone substitute
covered by conventional
membrane use for GBR




- Angiogenic and anti-fibrotic





AM as a scaffold for
bone tissue
engineering construct






2- Defect + cells










Inside the defect Seeded on a bone
substitute
1- Defect
2- Defect + AM cells
3- Defect + bone substitute
4- Defect + AM cells
seeded on the bone
substitute
5- Defect + hADSCs or
hBMSCs seeded on the
bone substitute
hADSCs, human adipose stromal cells; hBMSCs, human bone marrow stromal cells; GBR, guided bone regeneration.
other studies did not compare AM and seeded AM with the
condition “stromal cells only,” thereby making it impossible
to conclude on the action of stromal cells or AM. The last
point that prevents a conclusion from being drawn is related
to the fact that five different cell types were used with a wide
heterogeneity of culture duration on AM before implantation
(from 6 h to 4 weeks). Finally, one clinical trial successfully
used AM loaded with buccal fat pad-derived stromal cells
(BFSCs) to cover jaw-bone grafts. Among the various sources
of mesenchymal stromal cells proposed in bone regenerative
medicine, BFSCs display many advantages. They are isolated
from the intraoral sources of buccal fat pad that ensures low
morbidity after retrieval. BFSCs are thus an easily accessible
source of autologous stromal cells which can be readily used
for regeneration of craniofacial bone defects (Khojasteh et al.,
2019; Meshram et al., 2019). Besides, BFSCs display similar
expression level of RUNX-2, osteopontin, osteocalcin, and
ALP activity as BMSCs (Ardeshirylajimi et al., 2015), which
are currently used for bone tissue engineering approaches
(Lin et al., 2019; Kangari et al., 2020).
Various cell types have already been investigated for cell-
based bone tissue engineering approach, such as mesenchymal
stromal cells (especially bone marrow mesenchymal stromal
cells and adipose-derived stromal cells), induced pluripotent
stem cells or differentiated osteoblasts (Zhang et al., 2012).
This systematic review highlighted the potential of AM-
derived stromal cells for bone regenerative medicine. AM is
an attractive reserve of two pluripotent cell types for tissue
engineering: AECs and AMSCs (Parolini et al., 2009). Both
of them have demonstrated their ability to differentiate into
various cell types in vitro including osteogenic cells (Ilancheran
et al., 2007; Parolini et al., 2009). Besides, AECs and AMSCs
can be used safely. Unlike embryonic stem cells or induced
pluripotent stem cells, the in vivo teratoma formation and
tumorigenicity of AECs and AMSCs have not been reported
(Kang et al., 2012b; Rennie et al., 2012). Here, we showed
their effectiveness to promote bone healing in a supportive
environment. Indeed, the adjunction of AM-derived cells on
a scaffold, namely a bone substitute or fibrin-based scaffold,
implanted in a bone defect systematically increased bone
formation compared to the same scaffold implanted alone.
However, most of included studies showed limited size-samples.
It is also not possible to draw conclusions regarding the
superiority of one of the two cell types (AECs or AMSCs) as they
have never been directly compared in the same study. Besides,
comparative studies with the most widely studied sources of
mesenchymal stromal cells used in bone tissue engineering,
such as bone marrow or adipose tissue (Kangari et al., 2020),
are necessary to confirm these promising results. Finally, one
clinical trial is underway to evaluate the efficacy and safety
of human AECs transplant in non-union of limb fracture
patients (NCT03031509).
Few studies investigated the use of commercialized AM-
derived products for bone repair (Starecki et al., 2014; Konofaos
et al., 2015; Nunley et al., 2015). Pre-clinical studies showed
inconclusive results and the only clinical trial was conducted
without any control group. It is noteworthy that they all are
injectable products used as bone filling materials. Regarding
their authorization, even NuCel product is described as being
defined by US Food and Drug Administration (FDA) 21 CFR
Part 1271, these three commercialized products are currently
considered “investigational” (SURG.00011, 2020). We did not
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find clinical studies using commercial patented AM for guided
bone regeneration.
Finally, there were few limitations related to the present
study that must be mentioned. Firstly, we observed substantial
heterogeneity across the methodology of the selected studies,
thereby making it difficult to compare studies. Moreover, most
of the included articles showed low level of evidence due to the
limited number of animals or patients included per condition
and the lack of quantitative analysis or statistical significance.
Another identified drawback of this systematic review was the
higher number of animal studies included compared to clinical
studies across the selected studies. Most of the included studies
also lack data to support the benefit of AM anti-fibrotic and
angiogenic properties in the bone regeneration process. However,
this systematic review tried to provide some evidences on the
regenerative potential of AM and AM-derived products in vivo
and we proposed a clear guidance to perform further studies with
higher level of impact (Table 7).
CONCLUSION
The AM and its derivatives are an attractive source of biological
tissue and stromal cells for bone regeneration. Thanks to its low
immunogenicity, AM and its derivatives could be used either as
a xenograft or as an allograft. The lyophilized or decellularized-
lyophilized AM are a promising alternative to the commercial
membranes used for guided bone regeneration procedures and
achieved satisfactory outcomes in oral and maxillofacial surgery.
AM is mainly applied as a single layer and provide better
results when used as a membrane covering the defect rather
than as a filling material. It is better to decellularize AM to
enhance its potential to act as a natural scaffold seeded with
primary cells before its implantation in bone defects. AM-
derived stromal cells also showed their potential to be used
successfully in the field of bone regenerative medicine. For this
purpose, they have to be seeded on a scaffold, namely a bone
substitute. Studies investigating the potential of commercialized
AM-derived products were too limited and further studies are
required to draw some conclusions.
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